ArticleBMC cancer2022

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.

San-Chi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.